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PEDIATRIC UROLOGY
A Comparison Between Dextranomer/ Hyaluronic Acid and Polyacrylate Polyalcohol Copolymer as 
Bulking Agents for Treating Primary Vesicoureteral Reflux
Farshid Alizadeh1, Iman Omidi1, Saeid Haghdani2*, Mohammad Hatef Khorrami1, Mohammad Hossein 
Izadpanahi1, Mehrdad Mohammadi Sichani1
Purpose: In recent years, endoscopic subureteral injection has gained popularity as a therapeutic alternative to 
open surgery because of its high success rates and low morbidity. We compared the success and complication 
rates of Polyacrylate polyalcohol copolymer (PPC) and Dextranomer/Hyaluronic acid (Dx/HA) in the endoscopic 
treatment of VUR.
Materials & Methods: We retrospectively reviewed the patients who underwent endoscopic correction of their 
VUR by subureteric injection of PPC or Dx/HA from Jan 2010 to April 2016. The injection technique was STING 
(subureteric), distal HIT (intraureteric), and double HIT according the hydrodistention (HD) grade. The success 
rate, injection technique, injection volume, VUR grade, and obstruction rate were evaluated and compared between 
two groups.
Results: 107 renal refluxing units (RRU) with a mean age 55.23 ± 36.58 months and 64 RRU with a mean age 
52.13 ± 31.66 months were treated in Dx/HA and PPC groups, respectively. The PPC group showed a more suc-
cessful outcome in comparison to the Dx/HA group (92.2% versus 75.7% of the RRU with P < .001) at 3 months 
follow up. The injection technique was not significantly different between two groups. In PPC group the success 
rate was decreased significantly with increasing reflux grade but this reduction was not statistically significant in 
Dx/HA group. The injected volume was significantly more in PPC group; in addition, there was statistically sig-
nificant correlation between injected volume of the bulking agent and obstruction rate. However, the obstruction 
rate did not establish significant difference between the two groups (P = .83), however it was earlier in Vantris (4 
months versus 22 months).
Conclusion: Our investigation approved PPC as a more effective material, regardless of other confounding vari-
ables such as reflux grade, learning cure, and technique of injection, in endoscopic treatment of VUR. In addition, 
the other remarkable point is this effectiveness is not accompanied by more post-operation obstruction.
Keywords: vesicoureteral reflux; Dextranomer/ hyaluronic acid; polyacrylate polyalcohol copolymer; endoscop-
ic treatment
INTRODUCTION
Vesicoureteral reflux (VUR), the abnormal flow of urine from the bladder into the ureters or kidneys, 
is the most common urological anomaly in children(1). 
The primary goal of therapy in VUR is to prevent py-
elonephritis which can lead to long-term sequelaes 
such as renal scarring, hypertension, reduced somatic 
growth, renal insufficiency and end-stage renal disease 
(2,3). Treatment routes for VUR include observation, 
antibiotic prophylaxis, and surgical intervention(4,5). 
Ureteroneocystostomy is the gold standard of surgical 
therapy with the success rate of greater than 95%(6). In 
recent years, endoscopic subureteral injection has been 
introduced as a therapeutic alternative to open surgery 
because of its high success rates about 80-95%, low in-
cidence of complications, its minimally invasive nature 
and short hospital stay (7-9). This technique was initially 
described by Matouschek in 1981(10) and the first case 
series was reported by O’Donnell and Puri in 1984 (11). 
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Since then, different materials have been used in subu-
reteral injection which include: collagen, polytetrafluo-
roethylene (Teflon®)(12), polydimethylsiloxane (Mac-
roplastique®) (13), calcium hydroxyapatite (Coaptite®) 
(14), Dextranomer/Hyaluronic acid copolymer (Dx/HA, 
Deflux)(8) and recently, Polyacrylate polyalcohol copol-
ymer(15).
In 2001, the Food and Drug Administration approved 
Dextranomer/Hyaluronic acid copolymer (Deflux; 
Q-Med Scandinavia, Uppsala, Sweden) for subureter-
al injection and thereafter, the endoscopic management 
of VUR has emerged as a first line treatment of VUR 
worldwide(8).
Dx/HA is a viscous biocompatible gel consisting of 
dextranomer microspheres of 80 to 120 µm in diam-
eter and non-animal hyaluronic acid. The overall suc-
cess rate, depending on the VUR grade, stated in the 
literature ranges between 68 and 92% (9,16). In these 
conclusions, the long term recurrence rate of 10% to 
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26% with Dx/HA propel researchers into another tis-
sue-augmenting substance in order to reach better long-
term efficacy in the endoscopic treatment of VUR(16-19). 
Some have recommended that the biodegradable nature 
of Dx/HA is responsible for the concluding VUR recur-
rence (17).  Therefore, Polyacrylate polyalcohol copoly-
mer (PPC, Vantris, Promedon, Cordoba, Argentina) as 
a new non-biodegradable tissue-augmenting substance 
was developed. Polyacrylate Polyalcohol Copolymer 
is a biocompatible agent with an average diameter of 
300µm made of microparticles of PPC in glycerol and 
physiological solution (20). The overall success rate of 
PPC in the literature was reported to be between 83.6% 
and 94.9% in the short-term follow-up(15,20,21). In addi-
tion, one study with over three years follow up showed 
no VUR recurrence with PPC(21). The comparative stud-
ies between these two agents in literature are rare(22-24). 
There are controversial results in short term observa-
tions. While some studies presented PPC as the more 
successful substance, Pogorelic et al.(25) study showed 
no significant difference in cure rates between the Vur-
dex and PPC. In this study, we compared the success 
rate of PPC and Dx/HA in the endoscopic treatment of 
VUR with considering other suggested variables such 
as the injection technique and volume.
  
MATERIALS AND METHODS
We retrospectively reviewed the records of patients un-
der the age of 15 years who fulfilled inclusion criteria of 
the study and underwent endoscopic correction of their 
VUR by a single pediatric urologist (FA) from Jan 2010 
to April 2016. Before the April 2013, patients were 
treated by subureteric injection of PPC (43 patients, 64 
RRU) and after that time, by Dx/HA injection (65 pa-
tients, 107 RRU).
Inclusion criteria included patients with diagnosis of 
unilateral or bilateral primary VUR grades II–V with 
breakthrough UTIs despite prophylactic antibiotics, 
persistent VUR after a period of observation, poor com-
pliance with prophylactic antibiotics, and evidence of 
new renal scarring on a 99-m technetium dimercap-
to-succinic acid (DMSA) renal scan. Grade I VUR were 
treated only if accompanied by a contralateral higher 
grade reflux. 
The first evaluation of patients after UTI or finding of 
hydronephrosis on ultrasound study was with voiding 
cystourethrography (VCUG) and reflux grading was 
performed according to the International Classification 
System (International Reflux Study Committee). The 
preoperative work-up included a detailed history and 
physical examination, a VCUG, a urinalysis and cul-
ture. Before surgery, all patients were evaluated for the 
presence of neurologic deficits, dysfunctional voiding 
and/or constipation. If any symptoms of enuresis, noc-
turia, urgency, frequency (documented by a voiding di-
ary), postponement, holding maneuvers, urinary and/or 
fecal incontinence or constipation existed, a flowmetry/
pelvic floor electromyography (EMG) was performed 
to check for the presence of dysfunctional voiding 
(DV). This test was also performed if increased bladder 
wall thickness (>3 mm with full bladder) or increased 
post-void residual urine were observed on ultrasound in 
the absence of active UTI or bladder outflow obstruc-
tion. A formal pressure-flow study was performed in 
patients with significant bladder wall trabeculation on 
VCUG or documented neurological abnormalities. All 
patients with proven DV were first treated by biofeed-
back-assisted pelvic floor muscle training.
We considered the VUR to be secondary if it was ac-
companied by a known neurologic deficit, severe form 
of DV (Hinman syndrome) or documented urethral ob-
struction (e.g. posterior urethral valve). Exclusion cri-
teria were isolated grade I VUR, active UTI at the time 
of surgery, past history of open ureteroneocystostomy 
or subtrigonal injection of bulking agents, anatomical 
anomalies of the urinary tract (concomitant uretero-
pelvic junction obstruction, double urinary collecting 
system, ectopic ureter, posterior urethral valve) and 
alterations in bladder dynamics (untreated DV and neu-
ropathic bladder). 
The Committee of Ethics approved the protocol, and 
parents signed a written informed consent before op-
eration.
Technique
In the operation room, cystoscopy was performed by 
a 8-9.8 Fr offset lens, Wolf cystourethroscope and if 
the ureteral orifice was in the extravesical position (not 
diagnosed on VCUG), the patient was considered ineli-
gible for endoscopic surgery. 
The injection technique was STING (subureteric) in the 
absence of hydrodistention (HD) of the ureteral orifice, 
distal HIT (intraureteric) when the HD was grade 1 or 
2, and double HIT in the presence HD grade 3. A com-
bination of HIT and STING was used whenever a slit-
like orifice and disappearance of HD was not achieved 
by HIT alone. The material was injected until complete 
coaptation of the ureter was achieved and the type and 
volume of injected agent was recorded. The patient was 
discharged the evening of the day of surgery if no fever 
or significant hematuria was observed. After discharge 
from hospital, prophylactic oral cephalexin 15mg/Kg at 
bed time was prescribed until post-operative imaging 
showed reflux resolution or down-grading to Grade A 
on RNC.
Follow up study
Follow-up radionuclide cystography (RNC) was per-
formed 3 months after the operation or after any episode 
of febrile UTI in patients who had been cured of their 
reflux. According to the protocol, repeat RNC in cured 
patients was performed only in the presence of febrile 
UTI or new-onset hydroureteronephrosis (HUN). Renal 
and bladder ultrasound was performed at the post-oper-
ative month one, every 3 months during the first year, 
every 6 months during the next 2 years and then, yearly. 
If a new-onset HUN or exacerbation of the previous one 
was observed, a repeat RNC and a Lasix renogram was 
requested. We devided post-operative ureteral obstruc-
tion into early and late. Early-onset obstruction presents 
with renal colic in the early post-operative period and 
resolves spontaneously, while late-onset obstruction 
presents with urinary tract infection, creatinine rise (in 
bilateral cases) or as an incidental finding on post-op-
erative imaging. 
Success was defined as complete VUR resolution. In 
patients with bilateral reflux, if resolution occurred in 
one side, the operation was considered to be failed. 
Data were entered into the SPSS software (IBM Corpo-
ration, New York, United States), version 22. Fisher’s 
exact test, Mann-Whitney U test, t-test and one-way 
ANOVA were used for analyzing the data.
Bulking agents for treating primary vesicoureteral reflux-Alizadeh et al.
Pediatric Urology   176
RESULTS
One hundred and seven RRU and 64 RRU were treated 
in Dx/HA and PPC groups, respectively. The demo-
graphic data and patients’ characteristic are presented in 
Table 1. The success was achieved in 92.2% (59) RRU 
in PPC group and 75.7% (81) RRU in Dx/HA group (P 
< .001). 
By Mann-Whitney test, in reflux grade in PPC group 
the success rate was decreased significantly with in-
creasing reflux grade (P = .04) but this reduction was 
not statistically significant in Dx/HA group (P = .30). 
In post-operative period, early-onset obstruction was 
observed in 3 (4.7%) and 4 (3.7%) RRU in PPC and 
Dx/HA groups, respectively while late-onset ureteral 
obstruction occurred in 2 (3.1%) and 2 (1.9%) of RRU 
in PPC and Dx/HA groups, respectively. The obstruc-
tion rate did not establish significant difference between 
the two groups (P = .83). However, in patients with 
late-onset obstruction, the mean time from injection to 
obstruction was longer in Dx/HA group (22 moths vs. 
4 months).
The Spearman analysis showed statistically significant 
correlation between injected volume of the bulking 
agent and obstruction rate in PPC group (r=0.24, P = 
.04); however, the Dx/HA group failed to confirm this 
relationship (P = .52).
During the follow-up, 4 patients (10.2%) in the PPC 
group and 7 patients (18.4%) in the Dx/HA group who 
had been cured of their VUR, developed febrile UTI 
that underwent repeat RNC. One patient (25%) in the 
former group showed recurrence of VUR while this fig-
ure was 4 (57%) in the latter group. 
DISCUSSION
In our study the PPC group showed a more successful 
outcome (92.2% of the RRU and 90.6% of the patients) 
in comparison to the Dx/HA group (75.7% of the RRU 
and 58.4% of the patients). These results were in ac-
cordance with previous investigations. Karakus et al.(22) 
compared these two agents which revealed PPC promis-
es higher resolution rate than Dx/HA (88.6% vs 70.3%), 
although the former group had markedly higher uret-
erovesical junction obstruction. In another comparative 
study, reflux resolved after the first Deflux injection in 
63% of RRU and Vantris injection in 92.7% of RRU(24). 
However, in Turk et al. study(23) the overall treatment 
success rate was 79% in Dx/HA group and 81% in PPC 
group which was not significantly different. 
The overall success rate reported with use of Dx/HA 
ranged between 68–92% based on the VUR grade 
(8,16,24,26). One study that examined Dx/HA, demonstrat-
ed a success rate of 78.5% for grades I and II, 72% for 
grade III, 63% for grade IV and 51% for grade V reflux 
which revealed this hypothesis that increasing the grade 
of reflux decrease the success rate of treatment with this 
material(27). Although our result did not demonstrate any 
significant decrease in success rate in grade IV and V 
VUR in the Dx/HA group.
PPC comes from the family of Acrylics, particles of po-
lyacrylate polyalcohol copolymer immersed in a glyc-
erol and physiological solution carrier. When injected 
in soft tissues, it causes a bulkiness that remains sta-
ble(28). A multicentric study comprising 88 renal units 
treated with PPC showed the overall success rate about 
83.6%(20). In Sencan study(29), the accumulative suc-
cess rate after the injection of PPC at the end of the 
first year was 98.1%. Chertin et al. reported the success 
rate of PPC after a single injection as 94.9% (15). They 
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Table 1. Demographic data and patients’ characteristic in both groups.
 Characteristics  PPC group  Dx/HA group  P value
Mean Age (months)   52.13 ± 31.66 55.23 ± 36.58  0.57
Sex
 Male   10(15.6%)  22(20.6%)   0.54
 Female   54(84.4%)  85(79.4%) 
Laterality of VUR
    Left   35(54.7%)  53(49.5%)   0.53
    Right   29(45.3%)  54(50.5%)
Hx of UTI   60(93.8%)  81(75.7%)   0.003
pre-operative renal cortical scar  47(74.6%)  45(48.9%)   0.001
Variables   PPC group  Dx/HA group  P value
Injection technique        0.36
   HIT    16 (25%)  40 (37.4%)
   Double HIT   6 (9.4%)  11 (10.3%)
   STING   20 (31.2%)  25 (23.4%)
   HIT+STING   22 (34.4%)  31 (29%) 
Injected volume(mL)   0.78 ± 0.39  0.58 ± 0.30   0.001
VUR Grade (RRU)
   I    2 (3.1%)  6 (5.6%)   0.93
   II    11 (17.2%)  13 (12.1%)
   III    21 (32.8%)  42 (39.3%)
   IV    20 (31.2%)  27 (25.2%)
   V    10 (15.6%)  19 (17.8%)  
Follow up (months)   17.17 ± 12.81 18.81 ± 11.92  0.4
Table 2. Procedural detail in both groups.
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also demonstrate cure of reflux with a single injection 
in 92.1% of all patients in one year follow up. In War-
chol study, reflux resolved in 93% of all treated RRUs 
after first procedure, and in 100% after the second pro-
cedure. For high grade VUR, that is IV and V, success 
was achieved in almost 90% after the first injection and 
100% after the second injection(24). Chertin et al. eval-
uated prospectively the long term efficacy of PPC in 
children with VUR which showed no VUR recurrence 
in 3 years of follow-up, while recurrence rate with Dx/
HA ranges from 10% to 26% in long term follow up 
(21,30). Radiographic investigation in the Sedberry-Ross 
et al. and Swedish Reflux Study also demonstrated high 
radiographic recurrence (27%-38%) that was attributed 
to biodegradable nature of Dx/HA(31,32).
The use of PPC to correct grades IV and V is also very 
efficient with an overall success rate achieved of over 
80% (33,34). But in our study the success rate decreased 
in PPC (but not the Dx/HA) group significantly with 
increasing reflux grade.
Technique of injection is suggested as another variable 
for success rate of materials in recent literature. Single 
subureteral transurethral injection (STING) technique 
was used first time in 1984 for the endoscopic treat-
ment of pediatric VUR(35). The suggested injection site 
is 2 to 3 mm below the affected ureteric orifice, at the 
6 o’clock position. Hydrodistention Implantation Tech-
nique (HIT), which entails inserting the needle into the 
submucosal tunnel of the ureter via hydrodistention has 
been introduced in 2004 (16). Kirsh et al. by using Hy-
drodistention Implantation Technique injection (HIT), 
showed the short-term results with the endoscopic 
correction close to those results after open surgery. 
A success rate of 92% using the HIT procedure com-
pared with the 79% using the STING procedure was 
reported(16). Yucel et al.(36) and Watters et al.(37) found 
no differences on VUR resolution rate between the 
two techniques. Double Hydrodistention Implantation 
Technique was also described by these researchers (38). 
Double HIT, included two intraluminal ureteric tunnel 
injections which involves both proximal and distal in-
traureteral injections. Kalisvaart et al. revealed 96% 
clinical success with double HIT after 1 year of fol-
low-up(38). Akin et al.(39) observed a higher success rate 
with double HIT treatment compared to HIT. However, 
our data did not show significant difference between 
HIT and double HIT technique in either study groups.
Another important factor, predicting the success rate of 
the procedure, is learning curve. In our study groups 
this variable was omitted because the same surgeon did 
the procedure in both groups after passing the learning 
curve during the fellowship training program. In fact, 
although Dx/HA injection was done after PPC injec-
tion, this group had lower success rate. Therefore, the 
effect of surgeon’s experience as the cause of difference 
in success rate is precluded.
Complications following endoscopic injection are rare 
and including mainly obstruction of the vesicoureteric 
junction and development of a new contralateral VUR. 
In our Dx/HA group and PPC group 5.6% and 7.8% 
of patients developed obstruction respectively, with no 
statistically significant difference between them. Al-
though several variables involve in the likelihood of 
obstruction, the amount of injection material was not 
related to obstruction frequency in our data. There is not 
unanimous result in this field and controversial obser-
vations have been presented up to now(40). One differ-
ence was the mean time to obstruction that was longer 
in the Dx/HA group (22 vs. 4 months).  This finding 
suggest that long-term follow-up should be rigorous, 
especially in patients who receive Dx/HA. 
This study has some limitations such as small sample 
size of groups, lack of follow-up RNC after reflux res-
olution in all patients, non-randomized nature of the 
study and different inclusion criteria which contained 
more UTI history and scar formation in PPC group. 
These problems demand more studies with detailed date 
and longer follow up.
CONCLUSIONS
Our investigation approved PPC as a more effective 
material, regardless of other confounding variables 
such as reflux grade, learning cure, and technique of 
injection, in endoscopic treatment of VUR. In addition, 
the other remarkable point is this effectiveness is not 
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